Merus BV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $19.6100
- Today's High:
- $21.2600
- Open Price:
- $20.5300
- 52W Low:
- $13.46
- 52W High:
- $33.09
- Prev. Close:
- $20.5000
- Volume:
- 149257
Company Statistics
- Market Cap.:
- $0.918 billion
- Book Value:
- 7.12
- Revenue TTM:
- $0.053 billion
- Operating Margin TTM:
- -196.5%
- Gross Profit TTM:
- $-0.049 billion
- Gross Profit TTM:
- $-0.049 billion
- Profit Margin:
- -102.2%
- Return on Assets TTM:
- -15.7%
- Return on Equity TTM:
- -19.8%
Company Profile
Merus BV had its IPO on 2016-05-19 under the ticker symbol MRUS.
The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Merus BV has a staff strength of 0 employees.
Stock update
Shares of Merus BV opened at $20.53 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $19.61 - $21.26, and closed at $20.38.
This is a -0.59% slip from the previous day's closing price.
A total volume of 149,257 shares were traded at the close of the day’s session.
In the last one week, shares of Merus BV have slipped by -15.08%.
Merus BV's Key Ratios
Merus BV has a market cap of $0.918 billion, indicating a price to book ratio of 2.993 and a price to sales ratio of 17.41.
In the last 12-months Merus BV’s revenue was $0.053 billion with a gross profit of $-0.049 billion and an EBITDA of $-0.102 billion. The EBITDA ratio measures Merus BV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Merus BV’s operating margin was -196.5% while its return on assets stood at -15.7% with a return of equity of -19.8%.
In Q2, Merus BV’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.5%.
Merus BV’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.867 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merus BV’s profitability.
Merus BV stock is trading at a EV to sales ratio of 11.67 and a EV to EBITDA ratio of -6.02. Its price to sales ratio in the trailing 12-months stood at 17.41.
Merus BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Merus BV ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Merus BV ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Merus BV’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Merus BV's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Merus BV paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $20.38
- 52-Week High
- $33.09
- 52-Week Low
- $13.46
- Analyst Target Price
- $42.3
Merus BV stock is currently trading at $20.38 per share. It touched a 52-week high of $33.09 and a 52-week low of $33.09. Analysts tracking the stock have a 12-month average target price of $42.3.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Merus BV
Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)
Most Active
Top Gainers
Top Losers
About
Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.